Pfizer's migraine nasal spray gets FDA nod
The nasal spray offers a new way to administer CGRP drugs as migraine treatment.
by christian bundgaard, translated by daniel pedersen
Pfizer will soon be able to reap the rewards of last year’s huge acquisition of Biohaven. On Friday last week, Pfizer got its final approval for a Biohaven-developed nasal spray treatment for acute migraines, Zavzpret (zavegepant), reports industry media Endpoints News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
NICE recommends Lundbeck migraine drug
For subscribers
Denmark rejects reimbursement for migraine drug Aimovig
For subscribers
.jpg&w=384&q=75)
